http://ift.tt/eA8V8J
At the end of April, biotech company Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the FDA had accepted the resubmission of its Biologics License Application (BLA) for a drug called Kevzara.
read more
May 22, 2017 at 11:16PM
http://ift.tt/2qcTver
from Mark Collins
No comments:
Post a Comment